Kyowa Kirin Co., Ltd. (4151)

Name: Kyowa Kirin Co., Ltd. (4151) — storico dei bilanci
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Storico di ricavi, utili e flussi di cassa dai bilanci ufficiali.

Healthcare · Wall Street (USA) · Ultimo aggiornamento: 2026-10-02

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis.

Dati chiave

Capitalizzazione di mercato: JPY 1.17 trillion
Ricavi (esercizio chiuso a 2025-12-31): JPY 496.8B
Utile netto: JPY 67.0B
Margine lordo: 74.2%
Margine netto: 13.5%

Vedi grafici interattivi e bilanci completi → Modello di valutazione (DCF) →

Conto economico annuale

Conto economico	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Entrate totali	JPY 496.8B	JPY 495.6B	JPY 442.2B	JPY 398.4B
Utile lordo	JPY 368.9B	JPY 362.9B	JPY 331.0B	JPY 311.5B
Risultato Operativo (EBIT)	JPY 102.3B	JPY 91.9B	JPY 95.8B	JPY 82.4B
Reddito netto	JPY 67.0B	JPY 59.9B	JPY 81.2B	JPY 53.6B

Fonte: bilanci pubblici della società (SEC). Verificare su SEC EDGAR prima di fare affidamento su qualsiasi cifra.

Stati patrimoniali, flussi di cassa, dati trimestrali e indici completi nel visualizzatore interattivo di 4151. /companies/us/4151

Aziende simili

Le informazioni di questo sito sono solo a scopo educativo e informativo; non costituiscono consulenza finanziaria. Non vengono pubblicati prezzi obiettivo né raccomandazioni.

English version →Tutte le azioni

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.